Frontlight ResearchEarly access
CompletedPhase 1/2
NAD Supplementation and Vascular Health in PAD
Key facts
- Who runs it
- University of Oklahoma
- Where
- Oklahoma City, United StatesSee the site
- Trial code
- Status
- Completed
- Phase
- Phase 1/2
- People taking part
- 8 people enrolled
- Started
- 27 Feb 2023
- Ended
- 30 Dec 2024
- Type of study
- Interventional
- Treatments tested
- Nicotinamide riboside
- Record updated
- 6 April 2026
Who can take part
- Age
- 55 years to 99 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- diagnosis of PAD
- intermittent claudication
- limited walking capacity
Who cannot take part
- current or prior cerebrovascular complications (including large vessel ischemic stroke with chronic functional impairment)
- macologically uncontrolled type 2 diabetes, hypercholesterolemia, hypertension
- major depressive disorder
- neurodegenerative diseases
Where in United States
- University of Oklahoma Health Sciences CenterOklahoma City, United States
About the trial
What the trial wants to find out
This pilot open-label clinical trial was designed to investigate whether 4-week supplementation with 1g daily NR impacts endothelial function in peripheral circulation, cerebrovascular hemodynamics, cognitive function in older adults with peripheral artery disease.
The group in the trial
- NR supplementationTreatment being tested
1g daily NR
Treatment: Nicotinamide riboside
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- The Effect of Nicotinamide Adenine Dinucleotide (NAD) Supplementation on Systemic Vascular Health in Peripheral Artery Disease
- Record updated
- 6 April 2026